Lower urinary tract symptoms and benign prostatic hyperplasia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

About the authors

D. Yu Pushkar

P. I Rasner

References

  1. Избранные главы гериатрической урологии / под общ. ред. Л.М. Гориловского. М.: Ньюдиамед, 2000. 374 с.
  2. Мартов А.Г., Корниенко С.И., Гущин Б.Л. и др. Интраоперационные осложнения при трансуретральных оперативных вмешательствах по поводу доброкачественной гиперплазии предстательной (ТУР) железы. Урология. 2005;3-8.
  3. Руководство по урологии: В 3 т. / под общ. ред. Н.А. Лопаткина. М.: Медицина, 1998. Т. 3.
  4. Abrams P.H., Farrar D.J., Tumer-Warwick R.T. et al. The results ofprostatectomy: A symptomatic and urodynamic analysis of152 patients. J. Urol. 1979.;121:640-642.
  5. Ahmed M., Bell T., Lawrence W.T. et al. Transurethral microwavethermotherapy (Prostatron version 2.5) compared with transurethral resection of theprostate for the treatment of benign prostatic hyperplasia: A randomizedcontrolledparallel study. Br.J. Urol. 1997;79:181-185.
  6. Alsikafi N.F., Gerber G.S. Bilateral metachronous testicular seminomaassociated with microlithiasis. J. Urol. 1998;159:1643-1644.
  7. Barry M.J. Prostate specific antigen. Testing for early diagnosis of prostatecancer. N. Eng. J. Med. 2001;344:1373-1377.
  8. Barry M.J., Fowler F.J. Jr., O'Leary M.P. et al. The American UrologicalAssociation symptom index for benign prostatic hyperplasia. The MeasurementCommittee ofthe American Urological Association. J. Urol. 1992;148:1549-1557.
  9. Blanker M. H., Bohnen A. M., Groeneveld F. P. et al. Normal voiding patternsanddeterminants of increased diurnal and nocturnal voiding frequency in elderlymen. J. Urol. 2000;164:1201-1205.
  10. Boyle P. Epidemiology of benign prostatic hyperplasia: risk factors andconcomitance with hypertension. Br.J. Clin. Pract. 1994;74:18-22.
  11. Boyle P., Robertson C., Lowe F., Roehborn C. Meta-analysis of clinical trialsof Permixon in the treatment of benign prostatic hyperplasia. Urology.
  12. Brawer M.K. Diagnosis of lower urinary tract symptoms. Postgrad. Med.S pecial. Report. 1999:7-10.
  13. Cecil R.L. Cecil Textbook of Medicine. 20-th ed. Philadelphia: WBSaunders. 1996. 2233 p.
  14. Craigen A., Hickling J., Saunders C., Carpenter R. The natural history ofprostatic obstruction: A prospective survey. J.R. Coll. Gen. Pract. 1969;18:226-232.
  15. Djavan B., Roehrborn C.G., Shariat S. et al. Prospective randomizedcomparison of high energy transurethral microwave thermotherapy versus alphablocker treatment of patients with benign prostatic hyperplasia. J. Urol. 1999;161:139-143.
  16. Flanigan R.C., Reda D.J., Wasson J.H. et al. 5-year outcome of surgicalresection and watchful waiting for men with moderately symptomatic benignprostatic hyperplasia: А Department of Veterans Aff airs Cooperative Study. J. Urol. 1998;160:12-16.
  17. Francisca E.A., d'Ancona F. C., Meuleman E.J. et al. Sexual function followinghigh energy microwave thermotherapy: results of a randomized controlled studycomparing transurethral microwave thermotherapy to transurethral prostaticresection. J. Urol. 1999;161:486-490.
  18. Gerber G.S. Benign prostatic hyperplasia in older men. Clin. Geriatr.Med. 1998;14: 317-331.
  19. Girman C.J., Jacobsen S.J., Guess HA. et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow. J. Urol. 1995;153:1510-1515.
  20. Gormley G.J., Stoner E., Bruskewitz R.C. et al. The effect of finasteridein men with benign prostatic hyperplasia. The Finasteride Study Group. N.Eng. J. Med. 1992;327:1185-1191.
  21. Guess H.A. Epidemiology and natural history offbenign prostatic hyperplasia. Urol. Clin. North. Аm. 1995;22:247-261.
  22. Hoffman R. M., MacDonald R., Wilt T.J. Laser prostatectomy forbenignprostatic obstruction (Cochrane Review) The Cochrane Library. 2004;1:24.
  23. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate. 1989;2:33-50.
  24. Jensen K.M.-E. Clinical evaluation of routine urodynamic investigationsinprostatism. Neurourol. Urodynam. 1989;8:545-578.
  25. Kirby R., Boyle P., Fitzpatrick J. et al. Textbook of Benign ProstaticHyperplasia. - Oxford: Isis Medical Media, 1996. Р. 125-135.
  26. Lepor H., Williford W.O., Barry M.J. et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Aff airs CooperativeStudies Benign Prostatic Hyperplasia Study Group. N.Eng. J. Med. 1996;335:533-539.
  27. Lepor H., Williford W. O., Barry M. J. et al. The impact of medical therapyonbother due to symptoms, quality of life and global outcome, and factors predictingresponse. Veterans Affairs Oooperative Studies Benign Prostatic Hyperplasia StudyGroup. J. Urol. 1998;160:1358-1367.
  28. Lowe F.C., Fagelman E. Phytotherapy in the treatment of benign prostatichyperplasia: an update. Urology. 1999;53: 671-678.
  29. Matthiesen T.B., RittigS., Mortensen J.T., Djurhuus J.C. Nocturia and polyuriain men referred with lower urinary tract symptoms, assessed using a 7-dayfrequencyvolume chart. Br.J. Urol. Int. 1999;83:1017-1022.
  30. Medina J.J., Parra R.O., Moore R.G. Benign prostatic hyperplasia (theagingprostate). Med. Clin. North. А111. 1999;83:1213-1229.
  31. Meyhoff H.H., Ingemann L., Nordling J., Hald T. Accuracy in preoperativeestimation ofprostatic size. A comparative evaluation of rectal palpation, intravenouspyelography, urethral closure pressure profile recording andcystourethroscopy. Scand. J. Urol. Nephrol. 1981;15:45-51.
  32. Neal D.E., Ramsden P.D., Sharples L. et al. Outcome of electiveprostatectomy. BMJ. 1989;299:762-767.
  33. Neal D.E., Styles R.A., Powell P.H. et al. Relationship between voiding pressure, symptoms and urodynamic findings in 253 men undergoingprostatectomy. Br. J. Urol. 1987;60:554-559.
  34. Nyman M.A., Schwenk N.M., Silverstein M.D. Management ofurinaryretention: rapid versus gradual decompression and risk of complications. MayoClin. Proc. 1997;72: 951-956.
  35. Riehmann M., Knes J.M., Heisey D. et al. Transurethral resection versusincision of the prostate: a randomized, prospective study. Urology. 1995;45:768-775.
  36. Roehrborn C.G., Preminger G., Newhall P. et al. Microwave thermotherapyfor benign prostatic hyperplasia with the Dornier Urowave: Results of a randomizeddouble-blind multicenter sham-controlled trial. Urology. 1998;51:19-28.
  37. Rowan D., James E.D., Kramer A.E. et al. Urodynamic equipment: technicalaspects. Produced by the International Continence Society Working Party on Urodynamic Equipment. J.Med. Eng. Technol. 1987;11:57-64.
  38. Shingleton W.B., Farabaugh P., May W. Three-year follow-up of laserprostatectomy versus transurethral resection of the prostate in men with benignprostatic hyperplasia. Urology. 2002;60:305-308.
  39. Toscano I.L., Maciel L. C., Martins F.G. et al. Transurethral resection of theprostate: Prospective randomized study of catheter removal after 24 or 48 hours following surgery. Braz.J. Urol. 2001;27:144-147.
  40. Van Melick H.H., Van Venrooij G.E., Eckhardt M. D. et al. A randomizedcontrolled trial comparing transurethral resection of the prostate, contact laserprostatectomy and electrovaporization in men with benign prostatic hyperplasia: urodynamic effects. J. Urol. 2002;168:1058-1062.
  41. Van Venrooij G.E., Eckhardt M.D,, Gisholf K.W., Boon T.A. Data fromfrequency-volume charts versus symptom scores and quality of life score in menwith lower urinary tract symptoms due to benign prostatic hyperplasia. Eur.Urol. 2001;39:42-47.
  42. Wagrell L., Schelin S., Nordling J. et al. Feedback microwave thermotherapyversus TURP for clinical BPH: А randomized controlled multicenter study. Urology. 2002;60:292-299.
  43. Wasson J., Reda D., Bruskewitz R.C. et al. A comparison of transurethralsurgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia.The Veterans Affairs Cooperative Study Group on Transurethral Resection of theProstate. N.Eng. J. Med. 1994;334:75-79.
  44. Wilde M.I., Goa K.L. Finasteride: an update of its use in the management ofsymptomatic benign prostatic hyperplasia. Drugs. 1999;57:557-581.
  45. Wilt T., Ishani A., MacDonald R. Serenoarepensforbenignprostatichyperplasia (Cochrane Review). The Cochrane Library. 2004;1:24.
  46. Montorsi F. Summary of product characteristics. Eur. Urol. 2010;9:491-495.
  47. Management of non-neurogenic male lower urinary tract symptoms (luts) - update march 2017 http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
  48. Roehrborn C.G., et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-589.
  49. Boyle P., et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001;58(5):717-22.
  50. Roehrborn C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. EurUrol. 2010;57(1):123-131.
  51. Giuliano F. et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. EurUrol. 2013;63(3):506-516.
  52. Roehrborn C.G., et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-589.
  53. Boyle P., et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001;58(5):717-22.
  54. Roehrborn C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. EurUrol. 2010;57(1):123-131.
  55. Giuliano F. et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. EurUrol. 2013;63(3):506-516.
  56. Morelli A. et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011;8(10):2746-2760.
  57. Vignozzi L. et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73(13):1391-402.
  58. Ahyai S. A. et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement.Eur Urol. 2010;58(3):384-97.
  59. Madersbacher S. et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. EurUrol. 2005;47(4):499-504.
  60. Reich O. et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246-249.
  61. Madersbacher S. et al. Is transurethral resection of the prostate still justified? BJU Int. 1999;83(3):227-237.
  62. Naspro R. et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. EurUrol. 2006;50(3):563-568.
  63. Skolarikos A. et al. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol. 2008;22(10):2333-2340.
  64. Boyle P. et al. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int. 2004;94(1):83-88.
  65. Armitage J.N. et al. Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J Urol. 2007;177(5):1619-1624.
  66. Brown C.T. et al. Self management for men with lower urinary tract symptoms: randomized controlled trial. BMJ. 2007;334:25.
  67. Khullar V. et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283.
  68. Barendrecht M.M. et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 20084;27:226.
  69. Hsieh T.F. et al. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One, 2015;10.
  70. Gacci M. et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994.
  71. Nitti V.W. et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190:1320.
  72. Roehrborn C.G. et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116:450.
  73. Kim T.H. et al. Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an alpha-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial. BJU Int. 2016;117:307.
  74. Drake M.J. et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised D

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies